ABSTRACT
Benign focal liver lesions are frequently detected incidentally in clinical practice and represent a broad histopathological spectrum. In most cases, characteristic imaging findings allow for a non-invasive diagnosis; however, atypical appearances and rare lesions may pose diagnostic challenges in the differential diagnosis with malignancy. Although ultrasound is the first-line imaging modality, computed tomography and, in particular, multiparametric magnetic resonance imaging performed with hepatocyte-specific contrast agents play a central role in the detection, characterization, and differential diagnosis of these lesions. This review aims to summarize the imaging features of common lesions such as hemangioma, hepatocellular adenoma, and focal nodular hyperplasia, as well as rare benign focal liver lesions, and to highlight key points that aid in differential diagnosis.
Keywords:
Liver, benign lesion, US, CT, MRI
References
1
Oldhafer KJ, Habbel V, Horling K, Makridis G, Wagner KC. Benign liver tumors. Visc Med. 2020; 36: 292-303.
2
Jabiyev A, Karçaaltıncaba M, Karaosmanoğlu AD, Akata D, Özmen MN, İdilman İS. Multiparametric magnetic resonance imaging, diffusion-weighted magnetic resonance imaging, and magnetic resonance elastography: differentiating benign and malignant liver lesions. Diagn Interv Radiol. 2026; 32: 133-8.
3
Taouli B, Koh DM. Diffusion-weighted MR imaging of the liver. Radiology. 2010; 254: 47-66.
4
Baleato-González S, Vilanova JC, Luna A, Menéndez de Llano R, Laguna-Reyes JP, et al. Current and advanced applications of gadoxetic acid-enhanced MRI in hepatobiliary disorders. Radiographics. 2023; 43: e220087.
5
Arribas Anta J, Moreno-Vedia J, García López J, Rios-Vives MA, Munuera J, Rodríguez-Comas J. Artificial intelligence for detection and characterization of focal hepatic lesions: a review. Abdom Radiol (NY). 2025; 50: 1564-83.
6
Yin C, Zhang H, Du J, Zhu Y, Zhu H, Yue H. Artificial intelligence in imaging for liver disease diagnosis. Front Med (Lausanne). 2025; 12: 1591523.
7
Caseiro-Alves F, Brito J, Araujo AE, Belo-Soares P, Rodrigues H, Cipriano A, et al. Liver haemangioma: common and uncommon findings and how to improve the differential diagnosis. Eur Radiol. 2007; 17: 1544-54.
8
Mamone G, Di Piazza A, Carollo V, Cannataci C, Cortis K, Bartolotta TV, et al. Imaging of hepatic hemangioma: from A to Z. Abdom Radiol (NY). 2020; 45: 672-91.
9
Gore RM, Newmark GM, Thakrar KH, Mehta UK, Berlin JW. Hepatic incidentalomas. Radiol Clin North Am. 2011; 49: 291-322.
10
Di Carlo I, Koshy R, Al Mudares S, Ardiri A, Bertino G, Toro A. Giant cavernous liver hemangiomas: is it the time to change the size categories? Hepatobiliary Pancreat Dis Int. 2016; 15: 21-9.
11
Reizine E, Mulé S, Luciani A. Focal benign liver lesions and their diagnostic pitfalls. Radiol Clin North Am. 2022; 60: 755-73.
12
Gatti M, Maino C, Tore D, Carisio A, Darvizeh F, Tricarico E, et al. Benign focal liver lesions: the role of magnetic resonance imaging. World J Hepatol. 2022; 14: 923-43.
13
Vilgrain V, Boulos L, Vullierme MP, Denys A, Terris B, Menu Y. Imaging of atypical hemangiomas of the liver with pathologic correlation. Radiographics. 2000; 20: 379-97.
14
Ridge CA, Shia J, Gerst SR, Do RK. Sclerosed hemangioma of the liver: concordance of MRI features with histologic characteristics. J Magn Reson Imaging. 2014; 39: 812-8.
15
Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, Valla D, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology. 2009; 137: 1698-705.
16
Ronot M, Vilgrain V. Imaging of benign hepatocellular lesions: current concepts and recent updates. Clin Res Hepatol Gastroenterol. 2014; 38: 681-8.
17
Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, et al.; GENTHEP Investigators. Molecular classification of hepatocellular adenoma associates with risk factors, bleeding, and malignant transformation. Gastroenterology. 2017; 152: 880-94.e6.
18
Bioulac-Sage P, Gouw ASH, Balabaud C, Sempoux C. Hepatocellular adenoma: what we know, what we do not know, and why it matters. Histopathology. 2022; 80: 878-97.
19
Bise S, Frulio N, Hocquelet A, Alberti N, Blanc JF, Laurent C, et al. New MRI features improve subtype classification of hepatocellular adenoma. Eur Radiol. 2019; 29: 2436-47.
20
Auer TA, Fehrenbach U, Grieser C, Penzkofer T, Geisel D, Schmelzle M, et al. Hepatocellular adenomas: is there additional value in using Gd-EOB-enhanced MRI for subtype differentiation? Eur Radiol. 2020; 30: 3497-506.
21
Ba-Ssalamah A, Antunes C, Feier D, Bastati N, Hodge JC, Stift J, et al. Morphologic and molecular features of hepatocellular adenoma with gadoxetic acid-enhanced MR imaging. Radiology. 2015; 277: 104-13.
22
Reizine E, Ronot M, Pigneur F, Purcell Y, Mulé S, Dioguardi Burgio M, et al. Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping. Eur Radiol. 2019; 29: 3791-801.
23
Tse JR, Felker ER, Naini BV, Shen L, Shen J, Lu DSK, et al. Hepatocellular adenomas: molecular basis and multimodality imaging update. Radiographics. 2023; 43: e220134.
24
Tse JR, Naini BV, Lu DS, Raman SS. Qualitative and quantitative gadoxetic acid-enhanced MR imaging helps subtype hepatocellular adenomas. Radiology. 2016; 279: 118-27.
25
Lee SY, Kingham TP, LaGratta MD, Jessurun J, Cherqui D, Jarnagin WR, et al. PET-avid hepatocellular adenomas: incidental findings associated with HNF1-α mutated lesions. HPB (Oxford). 2016; 18: 41-8.
26
Laumonier H, Cailliez H, Balabaud C, Possenti L, Zucman-Rossi J, Bioulac-Sage P, et al. Role of contrast-enhanced sonography in differentiation of subtypes of hepatocellular adenoma: correlation with MRI findings. AJR Am J Roentgenol. 2012; 199: 341-8.
27
Julien C, Le-Bail B, Ouazzani Touhami K, Frulio N, Blanc JF, Adam JP, et al. Hepatocellular adenoma risk factors of hemorrhage: size is not the only concern!: single-center retrospective experience of 261 patients. Ann Surg. 2021; 274: 843-50.
28
Fujita N, Nishie A, Asayama Y, Ishigami K, Ushijima Y, Kakihara D, et al. Hyperintense liver masses at hepatobiliary phase gadoxetic acid-enhanced MRI: imaging appearances and clinical importance. Radiographics. 2020; 40: 72-94.
29
Reizine E, Ronot M, Ghosn M, Calderaro J, Frulio N, Bioulac-Sage P, et al. Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma. Eur Radiol. 2021; 31: 3417-26.
30
Zulfiqar M, Sirlin CB, Yoneda N, Ronot M, Hecht EM, Chernyak V, et al. Hepatocellular adenomas: understanding the pathomolecular lexicon, MRI features, terminology, and pitfalls to inform a standardized approach. J Magn Reson Imaging. 2020; 51: 1630-40.
31
Choudhry Z, Rikani AA, Choudhry AM, Tariq S, Zakaria F, Asghar MW, et al. Sonic hedgehog signalling pathway: a complex network. Ann Neurosci. 2014; 21: 28-31.
32
Sciarra A, Schmidt S, Pellegrinelli A, Maggioni M, Dondossola D, Pasquier J, et al. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy. Liver Int. 2019; 39: 158-67.
33
Roux M, Pigneur F, Calderaro J, Baranes L, Chiaradia M, Tselikas L, et al. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI. J Magn Reson Imaging. 2015; 42: 1249-58.
34
European Association for the Study of the Liver (EASL). EASL Clinical Practice Guidelines on the management of benign liver tumours. J Hepatol. 2016; 65: 386-98.
35
LeGout JD, Bolan CW, Bowman AW, Caserta MP, Chen FK, Cox KL, et al. Focal nodular hyperplasia and focal nodular hyperplasia-like lesions. Radiographics. 2022; 42: 1043-61.
36
Wanless IR. The pathogenesis of focal nodular hyperplasia of the liver. J Gastroenterol Hepatol. 2004; 19: S342-3.
37
Mortelé KJ, Praet M, Van Vlierberghe H, Kunnen M, Ros PR. CT and MR imaging findings in focal nodular hyperplasia of the liver: radiologic-pathologic correlation. AJR Am J Roentgenol. 2000; 175: 687-92.
38
van Kessel CS, de Boer E, ten Kate FJ, Brosens LA, Veldhuis WB, van Leeuwen MS. Focal nodular hyperplasia: hepatobiliary enhancement patterns on gadoxetic-acid contrast-enhanced MRI. Abdom Imaging. 2013; 38: 490-501.
39
Bröker MEE, Klompenhouwer AJ, Gaspersz MP, Alleleyn AME, Dwarkasing RS, Pieters IC, et al. Growth of focal nodular hyperplasia is not a reason for surgical intervention, but patients should be referred to a tertiary referral centre. World J Surg. 2018; 42: 1506-13.
40
Calame P, Tyrode G, Weil Verhoeven D, Félix S, Klompenhouwer AJ, Di Martino V, et al. Clinical characteristics and outcomes of patients with hepatic angiomyolipoma: a literature review. World J Gastroenterol. 2021; 27: 2299-311.
41
Tan Y, Xiao EH. Hepatic perivascular epithelioid cell tumor (PEComa): dynamic CT, MRI, ultrasonography, and pathologic features--analysis of 7 cases and review of the literature. Abdom Imaging. 2012; 37: 781-7.
42
Anderson SW, Kruskal JB, Kane RA. Benign hepatic tumors and iatrogenic pseudotumors. Radiographics. 2009; 29: 211-29.
43
Makino Y, Miyazaki M, Shigekawa M, Ezaki H, Sakamori R, Yakushijin T, et al. Solitary fibrous tumor of the liver from development to resection. Intern Med. 2015; 54: 765-70.
44
Yugawa K, Yoshizumi T, Mano Y, Kurihara T, Yoshiya S, Takeishi K, et al. Solitary fibrous tumor in the liver: case report and literature review. Surg Case Rep. 2019; 5: 68.
45
Rouy M, Guilbaud T, Birnbaum DJ. Liver solitary fibrous tumor: a rare incidentaloma. J Gastrointest Surg. 2021; 25: 852-3.
46
Stanietzky N, Salem AE, Elsayes KM, Rezvani M, Fraivillig K, Salem U, et al. Tumor-like conditions that mimic liver tumors. Diagn Interv Radiol. 2025; 31: 285-94.
